Alan Colowick

Board Director

Director

Personalis, Inc.Personalis, Inc.Alumis Inc.Harpoon Therapeutics, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 1 buy · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€104k

▼ Sales (0 ops.)

—

Latest filing published 03 Apr 2025 for ALUMIS INC., €104k. Read the official filing

Filing timeline

BuySale

Alan Colowick

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Alan Colowick: trading record in brief

Alan Colowick (board member) discloses dealings in 3 companies, chiefly Personalis, Inc., Alumis Inc. and Harpoon Therapeutics, Inc. The record holds 4 filings, for trades running from 14 May 2021 to 1 April 2025.

Purchases make up the whole of the open-market record (1 purchase, €104k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 3 share grants. In 2025 alone, the filings show 1 purchase and no sales.

The newest entry dates from 3 April 2025: an open-market purchase of €104k, in Alumis Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.